Linde plc (LIN)
NEUTRALFundamental
66
Preço
$486.14
Capitalização de Mercado
$225.89B
Parte 1 · Quanto vale a empresa
Visão Geral
Linde produces and delivers industrial gases — oxygen, nitrogen, hydrogen, argon and carbon dioxide, among others — that manufacturers, hospitals, refineries and electronics makers need to run their processes but rarely make themselves. It supplies large customers through dedicated on-site plants built next to their facilities, smaller customers by tanker truck or cylinder, and also has an Engineering unit that designs and builds gas-production plants for third parties, including rival gas companies.
Como gera receita
Most revenue comes from long-term, often 15-to-20-year, on-site contracts with take-or-pay minimums that pay Linde whether or not the customer uses the full volume, plus merchant sales of liquefied gas delivered by truck and cylinder gas sold to smaller accounts. Energy and raw-material costs are largely passed through to customers contractually. The Engineering segment instead books lumpy, project-based revenue as it designs and constructs plants, unrelated to the recurring gas-supply business.
Receita por segmento
Gas production and distribution across North and South America, Linde's largest geographic segment.
Gas production and distribution across Europe, the Middle East and Africa.
Gas production and distribution across Asia Pacific, including electronics and metals customers.
Designs and builds gas-production plants for third-party customers, including other industrial-gas companies.
Corporate and other smaller activities not allocated to a geographic or engineering segment.
Vantagem competitiva
Custos de mudança · AmplaLinde's on-site plants are built inside a customer's own facility and connected by pipeline, so switching supplier means relocating an entire gas plant — practically never done once a contract is signed. Combined with a dense, hard-to-replicate network of pipelines and distribution routes built up over decades, this gives Linde a durable, structural advantage over smaller or newer competitors.
O que impulsiona a procura
Moderadamente cíclicoDemand is a mix: healthcare and food-grade gases are fairly stable through economic cycles, while sales to chemicals, metals and mining, and energy customers rise and fall with those industries' own investment cycles. Long-term take-or-pay contracts smooth some of this volatility, but the Engineering segment's project backlog can still slow if large customers delay capital projects.
Principais riscos
- Energy is the largest cost input — Electricity, natural gas and diesel for distribution are Linde's single largest cost item; while contracts pass through much of this cost, unmitigated spikes or supply disruptions can still hurt margins.
- Cyclical industrial end markets — Customers in chemicals and energy, and metals and mining are cyclical businesses, and a downturn in these industries reduces the volumes Linde sells and can delay new on-site project starts.
- Large project backlog execution risk — Linde is building a multibillion-dollar backlog of large on-site and engineering projects; delays, cost overruns, or a customer's own project being cancelled or downsized would slow the growth these projects are meant to deliver.
- Global operating and regulatory exposure — Operating plants and distribution networks across dozens of countries exposes Linde to currency movements, local regulation and geopolitical disruption in any single market where it has significant invested capital.
Os argumentos a favor
Buyers argue that pipeline-connected, take-or-pay contracts make Linde's core revenue unusually predictable for an industrial company, that a multibillion-dollar project backlog gives visibility into several years of growth, and that scale and route density make Linde structurally hard for smaller gas suppliers to dislodge from existing customer sites.
Os argumentos contra
Sellers fear that a meaningful share of volumes still depends on cyclical chemicals, metals and energy customers who can cut back sharply in a downturn, that energy-cost pass-through contracts do not fully protect margins in extreme price spikes, and that the large project backlog carries execution and customer-cancellation risk over a multi-year build-out.
Written by the editors, published on 18 de agosto de 2026
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balanço & Liquidez
Receita
$35.45B
Últimos 12 meses (até 30/06/2026)
Resultado Líquido
$7.24B
Últimos 12 meses (até 30/06/2026)
Fluxo de Caixa Livre
$5.09B
Capital Próprio Total
$38.24B
Passivo Total
$47.08B
Rácio de Liquidez
0.88
Cobertura de Juros
37.36
Dívida/EBITDA
2.59
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$658.45
Preço Atual
$486.14
Margem de Segurança
+26.2%
Intervalo de Valor Justo
$476.00 - $840.89
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
31.61
ROE
18.0%
Rácio P/B
5.78
P/FCF
45.41
Margem Bruta
-
ROIC
10.3%
Radar de Rentabilidade
Value Creation (Economic Moat)
ROIC
10.3%
WACC
7.4%
ROIC − WACC
+2.9 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Critérios de Análise Fundamental
Aprovado (17)
- EPS shows upward trend
- EPS CAGR 12.14%
- Price CAGR 15.32%
- ROIC 10.3%
- Debt/Equity ratio
- Operating Margin 26.5%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 18.8%
- Analyst Consensus 73% Buy
- PEG Ratio 1.20
- Earnings Quality (OCF/NI) 1.45
- Share Dilution -2.0%
- Net Margin Trend 20.4% vs 20.2%
Reprovado (9)
- P/FCF 45.41
- P/B Ratio 5.78
- CapEx intensity
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Revenue Growth 5Y 4.5%
- Earnings Surprise avg -0.2%
- Piotroski F-Score 4/9
Indisponível (2)
- Gross Margin NaN%
- Dividend Payout NaN%
Piotroski F-Score
Sinais mistos: algumas áreas requerem atenção
Qualidade dos Resultados
Alta qualidade: resultados respaldados por caixa
Diluição de Ações
A recomprar ações. Favorável ao acionista
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Mr. Sanjiv Lamba | CEO & Chairman of the Board | 61 |
| Mr. Matthew J. White C.F.A. | Executive VP & CFO | 53 |
| Mr. Sean F. Durbin | COO & EVP | 54 |
| Mr. Guillermo Bichara | Executive VP & Chief Legal Officer | 50 |
| Mr. Benjamin W. Glazer | Senior VP of Americas | 51 |
| Denny Brown | Chief Accounting Officer | - |
| Mr. Juan Pelaez | Vice President of Investor Relations | - |
| Karin Griggel | Chief Compliance Officer | - |
| Ms. Desiree Co Bacher | Senior VP & Chief Human Resources Officer | 54 |
| Mr. Moloy Banerjee | President of ASEAN & South Asia | 59 |
Risco de Auditoria
10
Risco do Conselho
8
Risco de Remuneração
1
Risco dos Direitos dos Acionistas
4
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Latest News
Recent headlines for LIN, sourced from Markets Gazette.
- 4/1/2026POSITIVEHere's How Much You Would Have Made Owning Linde Stock In The Last 10 Years
Linde plc has demonstrated significant long-term value for its shareholders, with returns over the past decade indicating a robust performance. While specific figures are not detailed in the provided snippet, the title suggests substantial gains for investors who held Linde stock over the last 10 years. This historical performance underscores the company's stability and growth potential within the industrial gases sector. Investors looking for established companies with a track record of delivering shareholder value may find Linde an attractive option, especially given its essential role in various industrial processes.
- 3/6/2026NEGATIVEMedtronic Diabetes Unit MiniMed Falls 2% After $560 Million IPO
MiniMed Group Inc., a newly separated diabetes management unit from Medtronic Plc, experienced a 2% decline in its stock price during its trading debut. The company successfully raised $560 million through its initial public offering. The initial dip suggests a lukewarm market reception or profit-taking by early investors, despite the significant capital raised. For investors, this initial performance indicates potential short-term volatility and highlights the importance of monitoring post-IPO performance closely.
via Markets Gazette